- Zacks•8 days ago
Supernus Pharmaceuticals, Inc. (SUPN) announced encouraging top-line data from a phase IIb dose-ranging study (n=222) on one of its lead pipeline candidate.
- Investor's Business Daily•9 days ago
Biotechnology was the worst-performing group in the stock market Wednesday, as political fears weighed.
- Investopedia•9 days ago
Supernus Pharmaceuticals said mid-stage trials of its ADHD drug, SPN-812, showed good results. The company plans to launch Phase III trials in 2017.
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||20.81 x 300|
|Ask||22.00 x 100|
|Day's Range||20.45 - 21.12|
|52wk Range||9.51 - 26.84|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||42.51|
|Avg Vol (3m)||643,981|
|Dividend & Yield||N/A (N/A)|